ID
4848
Beskrivning
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.
Länk
http://clinicaltrials.gov/ct2/show/study/NCT00048295
Nyckelord
Versioner (1)
- 2014-04-11 2014-04-11 - Julian Varghese
Uppladdad den
11 april 2014
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility NCT00048295 Crohns Disease
Eligibility NCT00048295
- StudyEvent: Eligibility
Beskrivning
Exclusion
Beskrivning
Severe intestinal stenosis
Datatyp
boolean
Alias
- UMLS CUI-1
- C0521587
Beskrivning
External fistulization
Datatyp
boolean
Alias
- UMLS CUI-1
- C0016169
Beskrivning
Infection
Datatyp
boolean
Alias
- UMLS CUI-1
- C0009450
Beskrivning
Malignancy
Datatyp
boolean
Alias
- UMLS CUI-1
- C0006826
Beskrivning
Bleeding problem
Datatyp
boolean
Alias
- UMLS CUI-1
- C0005779
Similar models
Eligibility NCT00048295
- StudyEvent: Eligibility
C1456820 (UMLS CUI-2)
C0021469 (UMLS CUI-3)